12 citations
,
October 1978 in “PubMed” Ro 10-9359 is an effective treatment for severe psoriasis but can cause side effects.
February 2025 in “Skin Appendage Disorders” Upadacitinib helps most people with alopecia regrow hair quickly and is generally safe.
February 2025 in “Revista Eletrônica Acervo Saúde” Triamcinolone hexacetonide is effective but has side effects, while PRP and minoxidil are safer alternatives for treating alopecia areata.
2 citations
,
September 2022 in “Annals of Oncology” Mirvetuximab soravtansine improves quality of life and reduces symptoms more than standard chemotherapy in ovarian cancer patients.
December 2020 in “Dermatología argentina” A patient got a skin reaction on their hands and feet after using secukinumab for psoriasis.
October 2023 in “Applied materials today” New treatment for hair loss using special microneedles shows promise in reducing inflammation and promoting hair growth.
6 citations
,
April 2013 in “Current Dermatology Reports” Dermatologists are crucial for managing skin side effects in metastatic melanoma patients using vemurafenib and ipilimumab.
February 2025 in “JDDG Journal der Deutschen Dermatologischen Gesellschaft” Deucravacitinib helped a man regrow hair and improve psoriasis.
2 citations
,
September 2021 in “JAAD case reports” Dupilumab helped a woman with severe hair loss regrow her hair quickly and maintain it for six months after stopping treatment.
12 citations
,
March 2021 in “JAAD Case Reports” Nail changes from immunotherapy can be managed without stopping cancer treatment.
June 2023 in “Brazilian Journal of Case Reports” Botulinum Toxin Type A delivered through the skin may be a promising treatment for Frontal Fibrosing Alopecia.
7 citations
,
January 2017 in “Dermatology Online Journal” TNF-inhibitor induced alopecia can be treated effectively with different therapies.
6 citations
,
March 2023 in “Journal of Ethnopharmacology” Jieduquyuziyin prescription helps treat SLE with atherosclerosis by improving cholesterol removal and reducing inflammation.
18 citations
,
February 2025 in “Drug Delivery and Translational Research” The microneedle patches effectively treat allergic conjunctivitis with controlled, sustained release of medication.
50 citations
,
July 2021 in “Nature Communications” The drug enzalutamide may reduce the ability of the virus causing COVID-19 to enter lung cells.
April 2017 in “Leukemia research” Tofacitinib helped most teenagers in the study regrow hair with mild side effects.
2 citations
,
April 2024 in “Advanced Materials” A microneedle patch can help regrow hair by restoring immune balance in hair follicles.
1 citations
,
September 2023 in “Journal of the American Academy of Dermatology” Guselkumab significantly improves quality of life for people with moderate to severe psoriasis.
147 citations
,
October 2021 in “Cancer Communications” RC48 shows promise for treating certain advanced cancers, but more research is needed.
22 citations
,
September 2020 in “The journal of investigative dermatology/Journal of investigative dermatology” The study's results on the effectiveness of low-dose IL-2 for alopecia areata and its impact on immune cells were not provided.
65 citations
,
February 2011 in “Molecular cancer therapeutics” CCT128930 is a promising new drug that effectively targets and inhibits a cancer-related protein, showing potential for cancer treatment.
3 citations
,
May 2022 in “Clinical and experimental dermatology” Drugs targeting EMT molecules show promise for treating lichen planopilaris.
66 citations
,
December 2018 in “Dermatology” Both ruxolitinib and tofacitinib are effective and safe for treating severe alopecia areata, but relapses are common.
October 2025 in “Figshare” Deuruxolitinib effectively treats alopecia areata but may cause manageable side effects.
September 2023 in “Acta dermato-venereologica” Tofacitinib is a safe and effective treatment for hair loss in children with Alopecia Areata.
Modern skin cancer treatments can cause skin side effects and hair loss, affecting patients' quality of life.
49 citations
,
December 2018 in “Journal of Investigational Allergology and Clinical Immunology” Dupilumab may cause hair loss in some patients with severe atopic dermatitis.
3 citations
,
October 1994 in “Journal of Dermatological Science” The new antibody, TYHF-1, specifically targets certain hair-related structures.
September 2022 in “Hair transplant forum international” JAK inhibitors like baricitinib are a new FDA-approved treatment for alopecia areata, but safety data is incomplete.
1 citations
,
May 2025 in “The Journal of Rheumatology” Careful monitoring is crucial to prevent JC virus reactivation in lupus patients treated with rituximab.